Literature DB >> 15048930

Axotomy-dependent and -independent synapse elimination in organ cultures of Wld(s) mutant mouse skeletal muscle.

Simon H Parson1, Richard R Ribchester, Neil Davie, Nirav P Gandhi, Rabia Q Malik, Thomas H Gillingwater, Derek Thomson.   

Abstract

Progressive "dying back" neurodegenerative diseases are debilitating due to loss of connectivity after nerve terminal and axonal withdrawal, which impairs peripheral nerve function and leads ultimately to neuronal cell death. The mutant mouse (Wallerian degeneration slow; Wld(s)) provides an accessible model system to understand orthograde and retrograde degeneration, because in these mice axotomy induces slow, progressive withdrawal of nerve terminals from motor endplates. Axon degeneration itself is about 10 times slower than in wild-type mice. We describe an organ culture paradigm that permits direct observation of the progressive changes in morphology of neuromuscular junctions in Wld(s) mutant mice. Normal nerve terminal and motor endplate morphology were maintained at most Wld(s) neuromuscular junctions for up to 72 hr in vitro. At others, synaptic boutons were removed from postsynaptic junctional folds in piecemeal fashion, as observed in adults in vivo. By contrast, nerve terminals degenerated rapidly and synchronously in wild-type muscle cultures, resembling Wallerian degeneration in vivo. These observations confirm that in Wld(s) mice, axotomy triggers a mechanism of nerve-terminal withdrawal that seems qualitatively different from that in wild-type animals. The piecemeal dismantling of presynaptic terminals resembles that occurring during neonatal synapse elimination. Organ cultures of neonatal Wld(s) muscle maintained for 1-2 days in vitro also showed no evidence of synaptic terminal degeneration, but elimination of polyneuronal innervation progressed in vitro at approximately the same rate as in vivo. Taken together, the data suggest that both natural and axotomy-induced forms of synapse withdrawal may be accessible to continuous observation and analysis, in organ-cultures of Wld(S) mouse muscles. This offers several advantages over repeated visualization of synaptic remodeling that has thus far been possible only in vivo. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15048930     DOI: 10.1002/jnr.20016

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  6 in total

1.  Rapid loss of motor nerve terminals following hypoxia-reperfusion injury occurs via mechanisms distinct from classic Wallerian degeneration.

Authors:  Becki Baxter; Thomas H Gillingwater; Simon H Parson
Journal:  J Anat       Date:  2008-06       Impact factor: 2.610

2.  Ex vivo imaging of motor axon dynamics in murine triangularis sterni explants.

Authors:  Martin Kerschensteiner; Miriam S Reuter; Jeff W Lichtman; Thomas Misgeld
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

Review 3.  Wallerian degeneration: an emerging axon death pathway linking injury and disease.

Authors:  Laura Conforti; Jonathan Gilley; Michael P Coleman
Journal:  Nat Rev Neurosci       Date:  2014-06       Impact factor: 34.870

4.  Activity-dependent degeneration of axotomized neuromuscular synapses in Wld S mice.

Authors:  R Brown; A Hynes-Allen; A J Swan; K N Dissanayake; T H Gillingwater; R R Ribchester
Journal:  Neuroscience       Date:  2015-01-21       Impact factor: 3.590

5.  NMJ-morph reveals principal components of synaptic morphology influencing structure-function relationships at the neuromuscular junction.

Authors:  Ross A Jones; Caitlan D Reich; Kosala N Dissanayake; Fanney Kristmundsdottir; Gordon S Findlater; Richard R Ribchester; Martin W Simmen; Thomas H Gillingwater
Journal:  Open Biol       Date:  2016-12       Impact factor: 6.411

6.  Dynamic remodelling of synapses can occur in the absence of the parent cell body.

Authors:  Natalia L Bettini; Thomas S Moores; Becki Baxter; Jim Deuchars; Simon H Parson
Journal:  BMC Neurosci       Date:  2007-09-26       Impact factor: 3.288

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.